Bale TA, Rosenblum MK (2022) The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol Zurich Switz 32:e13060. https://doi.org/10.1111/bpa.13060

Article  Google Scholar 

Reddy AT, Packer RJ (1999) Chemotherapy for low-grade gliomas. Childs Nerv Syst 15:506–513. https://doi.org/10.1007/s003810050539

Article  CAS  PubMed  Google Scholar 

Bouffet E, Jakacki R, Goldman S et al (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30:1358–1363. https://doi.org/10.1200/JCO.2011.34.5843

Article  CAS  PubMed  Google Scholar 

Ater JL, Zhou T, Holmes E et al (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the children’s oncology group. J Clin Oncol 30:2641–2647. https://doi.org/10.1200/JCO.2011.36.6054

Article  PubMed  PubMed Central  Google Scholar 

Lassaletta A, Scheinemann K, Zelcer SM et al (2016) Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a canadian pediatric brain tumor consortium study. J Clin Oncol 34:3537–3543. https://doi.org/10.1200/JCO.2016.68.1585

Article  CAS  PubMed  Google Scholar 

Ater JL, Xia C, Mazewski CM et al (2016) Nonrandomized comparison of neurofibromatosis type 1 and non–neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children’s Oncology Group. Cancer 122:1928–1936. https://doi.org/10.1002/cncr.29987

Article  CAS  PubMed  Google Scholar 

Gnekow AK, Walker DA, Kandels D et al (2017) A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma—a final report. Eur J Cancer 81:206–225. https://doi.org/10.1016/j.ejca.2017.04.019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pollack IF, Agnihotri S, Broniscer A (2019) Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr 23:261–273. https://doi.org/10.3171/2018.10.PEDS18377

Article  PubMed  PubMed Central  Google Scholar 

Jones DTW, Gronych J, Lichter P et al (2012) MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci CMLS 69:1799–1811. https://doi.org/10.1007/s00018-011-0898-9

Article  CAS  PubMed  Google Scholar 

EMA (2014) SUMMARY OF PRODUCT CHARACTERISTICS - MEKINIST. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Accessed 24 Jun 2024

Kim C, Giaccone G (2018) MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs 27:17–30. https://doi.org/10.1080/13543784.2018.1415324

Article  CAS  PubMed  Google Scholar 

Knispel S, Zimmer L, Kanaki T et al (2018) The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. Expert Opin Drug Saf 17:73–87. https://doi.org/10.1080/14740338.2018.1390562

Article  CAS  PubMed  Google Scholar 

Bouffet E, Geoerger B, Moertel C et al (2023) Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J Clin Oncol Off J Am Soc Clin Oncol 41:664–674. https://doi.org/10.1200/JCO.22.01000

Article  CAS  Google Scholar 

Perreault S, Larouche V, Tabori U et al (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer 19:1250. https://doi.org/10.1186/s12885-019-6442-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geoerger B, Moertel CL, Whitlock J et al (2018) Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN). J Clin Oncol 36:10537–10537. https://doi.org/10.1200/JCO.2018.36.15_suppl.10537

Article  Google Scholar 

Verheijen RB, Yu H, Schellens JHM et al (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102:765–776. https://doi.org/10.1002/cpt.787

Article  PubMed  PubMed Central  Google Scholar 

Mathijssen RHJ, Sparreboom A, Verweij J (2014) Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11:272–281. https://doi.org/10.1038/nrclinonc.2014.40

Article  CAS  PubMed  Google Scholar 

Ouellet D, Kassir N, Chiu J et al (2016) Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol 77:807–817. https://doi.org/10.1007/s00280-016-2993-y

Article  CAS  PubMed  Google Scholar 

Janssen JM, Dorlo TPC, Steeghs N et al (2020) Pharmacokinetic targets for therapeutic drug monitoring of small molecule kinase inhibitors in pediatric oncology. Clin Pharmacol Ther 108:494–505. https://doi.org/10.1002/cpt.1808

Article  PubMed  Google Scholar 

Anderson BJ, Holford NHG (2009) Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans. Drug Metab Pharmacokinet 24:25–36. https://doi.org/10.2133/dmpk.24.25

Article  CAS  PubMed  Google Scholar 

Le Louedec F, Puisset F, Thomas F et al (2021) Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr. CPT Pharmacomet Syst Pharmacol 10:1208–1220. https://doi.org/10.1002/psp4.12689

Article  CAS  Google Scholar 

mekinist-epar-product-information_en.pdf

Van Den Bent M, Wefel J, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583–593. https://doi.org/10.1016/S1470-2045(11)70057-2

Article  PubMed  Google Scholar 

Wen PY, Chang SM, Van Den Bent MJ et al (2017) Response assessment in neuro-oncology clinical trials. J Clin Oncol 35:2439–2449. https://doi.org/10.1200/JCO.2017.72.7511

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tipton J (2015) Overview of the challenges related to oral agents for cancer and their impact on adherence. Clin J Oncol Nurs 19:37–40. https://doi.org/10.1188/15.S1.CJON.37-40

Article  PubMed  Google Scholar 

Krohe M, Eek D, Mazar I et al (2016) Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence 10:1609–1621. https://doi.org/10.2147/PPA.S106629

Article  PubMed  PubMed Central  Google Scholar 

Groenland SL, Mathijssen RHJ, Beijnen JH et al (2019) Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur J Clin Pharmacol 75:1309–1318. https://doi.org/10.1007/s00228-019-02704-2

Article  PubMed  Google Scholar 

Géraud A, Combarel D, Funck-Brentano C et al (2024) A score to predict the clinical usefulness of therapeutic drug monitoring: application to oral molecular targeted therapies in cancer. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.3193

Article  PubMed  Google Scholar 

Bouffet E, Hansford JR, Garrè ML et al (2023) Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389:1108–1120. https://doi.org/10.1056/NEJMoa2303815

Article  CAS  PubMed  Google Scholar 

Hargrave DR, Terashima K, Hara J et al (2023) Phase II trial of dabrafenib plus trametin